Psychae Therapeutics focuses on developing medical-grade, botanically derived treatments to address serious mental health challenges.
Psychae Therapeutics has raised $2.9M in total funding. The most recent round was Pre-Seed. The last funding was announced in November 2023.
Psychae Therapeutics's investors include University of Melbourne, Tin Alley Ventures.
Psychae Therapeutics is headquartered in Carlton, Australia.
Psychae Therapeutics focuses on developing medical-grade, botanically derived treatments to address serious mental health challenges.
Psychae Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Psychae Therapeutics — Funding & Investors." VCBacked, November 13, 2023, https://www.vcbacked.co/company/psychae-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Psychae Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/psychae-therapeutics
{{cite web |title=Psychae Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/psychae-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated